-
-
PRODUCTS
-
-
RECRUITMENT
-
CONTACT
Disseminate company news and understand industry trends
First Generic Versions of Popular GLP-1 Agonist Expected to Launch in Q3 2025 Following Patent Expiry
Published Time:
2025-10-16
With a key patent expiring in August 2025, several generic drug manufacturers have received tentative FDA approval for their versions of a blockbuster GLP-1 receptor agonist. This is expected to significantly increase patient access to this class of diabetes and weight-management drugs starting in September.
Related News
Our company is committed to the development and research of medical technology, closely cooperating with key laboratories of surrounding universities, using many years of market resources, striving to improve the independent innovation ability of enterprises, keeping up with the development trend of the international pharmaceutical market, and constantly providing source of power for the development of enterprises.
Contact Information
D6-1104, Jiangsu Life Science and Technology Innovation Park, No. 9 Weidi Road, Qixia District, Nanjing
Copyright © 2025 Jiangsu Wanzhen Pharmaceutical Technology Co., Ltd.